Streetbeat News

LQDA

Liquidia Corporation

https://www.liquidia.com

Industry

Biotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Open

14.10

Mkt cap

1.2B

Volume

949K

High

14.47

P/E Ratio

-8.91

52-wk high

16.99

Low

14.05

Div yield

N/A

52-wk low

8.26

Liquidia (NASDAQ:LQDA) has received mixed analyst ratings over the past three months, with a total of 4 bullish and 1 somewhat bearish rating. The 12-month price target average has increased by 22.64% to $18.8, with a high of $30.00 and a low of $3.00. Analysts from Needham, Ladenburg Thalmann, B of A Securities, and Wedbush have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Liquidia is a biopharmaceutical company focusing on pulmonary hypertension treatments and has shown a revenue growth rate of 16.21% as of September 30, 2023, but trails behind industry peers and has a net margin of -429.31% and ROE of -29.06%.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 1:00 pm

Needham analyst Serge Belanger has maintained a Buy rating on Liquidia (NASDAQ:LQDA) and increased the price target from $18 to $28.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 11:25 am

Liquidia Corporation (NASDAQ:LQDA) has secured $100M in new financings, comprising a $75M private placement of common stock to a Patient Square Capital fund and a $25M advance from HealthCare Royalty. The stock sale is at an 8% discount to the prior closing price, and the advance is part of an existing agreement. These funds will support Liquidia's objectives for 2024, potentially leading to profitability with the launch of YUTREPIA for PAH and PH-ILD treatment. Liquidia has raised a total of $126M in recent financings.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 2:15 pm

Liquidia Corp has filed with the SEC for a mixed shelf offering, allowing the company to issue various types of securities up to a total of $200 million.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 9:13 pm

Ladenburg Thalmann analyst Matthew Kaplan has reaffirmed a Buy rating on Liquidia (NASDAQ:LQDA) and increased the price target from $15 to $30.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 6:44 pm

B of A Securities has reaffirmed its Buy rating on Liquidia (NASDAQ:LQDA) and increased its price target from $13.00 to $15.00. Liquidia's shares have risen 3.46% in the last 24 hours to $11.07. The new price target suggests a potential upside of 35.5%. Liquidia is a biopharmaceutical company focusing on pulmonary hypertension treatments, utilizing its proprietary PRINT technology.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 5:00 pm

B of A Securities analyst Greg Harrison has reaffirmed a Buy rating on Liquidia (NASDAQ:LQDA) and increased the price target from $13 to $15, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 4:24 pm

Wedbush analyst Andreas Argyrides has reiterated an Underperform rating on Liquidia (NASDAQ:LQDA) and maintained a price target of $3.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 2:06 pm

The Federal Circuit has affirmed an earlier PTAB decision to invalidate all claims of United Therapeutics' patent No. 10,716,793. Liquidia will seek to lift the injunction imposed by the District Court in Delaware and continue pursuing FDA approval for YUTREPIA.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 9:58 pm

Liquidia Corp (LQDA) stock surged following a favorable ruling in a patent dispute with United Therapeutics Corporation (UTHR) over the '793 patent related to pulmonary hypertension treatment. The panel affirmed the Board's unpatentability determination, which is a positive development for Liquidia. United Therapeutics owns the patent for treprostinil, marketed as Tyvaso, and had initiated Hatch-Waxman litigation against Liquidia's Yutrepia. Despite the tentative FDA approval for Yutrepia, its market release is pending until the litigation and exclusivity period for Tyvaso expire. LQDA's stock price increased by 42.80%, while UTHR's stock fell by 4.39%.

Portfolio Pulse from Vandana Singh

December 20, 2023 | 7:04 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.